Inhibition of the Notch Pathway Promotes Flap Survival by Inducing Functional Angiogenesis

To the Editor:

With interest, we read the recently published manuscript entitled "Inhibition of the Notch Pathway Promotes Flap Survival by Inducing Functional Angiogenesis."[1]

The authors conclude that intravenous injection of the γ secretase inhibitor (GSI) DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl Ester) promotes skin flap survival and functional neovascularization by inhibition of the Notch signaling pathway.

Despite the authors' statement that little is known on the role of Notch in ischemia-induced angiogenesis, in-depth studies on the topic exist. It is known that a genetic lack of Notch signaling by the deficiency of the ligand Dll1 leads to detrimental tissue necrosis with loss of limbs in the hindlimb ischemia model.[2] In genetic gain and loss of function models of the Notch ligand Dll4 in different established models of ischemia, perfusion, or clinical outcome did not improve.[3] Similarly, DLL4 inhibition causes formation of a more numerous but disorganized capillary network in ischemic muscles.[4] Several groups have found that blockade of Notch signaling genetically and pharmacologically leads to disorganized and unproductive endothelial growth, which results in tumor hypoxia and necrosis.[5] Overall, the homeostasis of tissues by Notch signaling is complexly organized but a teamed effort by Notch ligands and Notch signaling restricts branching and is required to generate functional, perfused vessels.[6]

That pharmacological Notch inhibition should result in a beneficial clinical outcome in the reported surgical flap model is conceptually surprising and technically not sufficiently elaborated.

First and foremost, the γ-secretase cleaves several proteins, including Notch, E-cadherin, CD44, and erythroblastic leukemia viral oncogene homolog 4, which are all important modulators of angiogenesis.[7] The use of the GSI DAPT is thus unspecific, and the observed effects cannot be attributed to Notch signaling only.

This is the reason why relevant data on the role of Notch signaling in ischemia- and tumor-induced angiogenesis have been generated in genetic models of Notch signaling using effective γ-secretase inhibition only in addition.

In this context, it is stated that treatment with the GSI DAPT was given by intravenous injection. The substance is not soluble in aqueous solutions but needs to be solved in dimethyl sulfoxide. A more detailed protocol would be worth publishing alongside this manuscript. Furthermore, no evidence is provided that the chosen treatment protocol indeed inhibits Notch activity in vivo, for instance, data on Notch target gene expression in the flap model are not shown.

Interestingly, measurements of DLL4 protein levels in blood are presented as increased. However, DLL4 is a membrane-bound ligand, so detection of circulating DLL4 would indicate shedded ligands. The relationship to tissue expression levels are unclear and thus the relevance of the presented data.

We would like to point out that the model of Notch-DLL4 crosstalk in sprouting angiogenesis presented in Figure 1 is not timely and has recently been revised. The DLL4 expression in tip cells is only weakly modulated by vascular endothelial growth factor receptor 2 (VEGFR2). Notch signaling has little impact on VEGFR2 transcription but it strongly modulates VEGFR3.[8]

In the presented flap model, an increase of capillaries is noted with DAPT treatment. Because perfusion is not regulated at the level of capillaries,[9] the significance for flap perfusion is at best unclear. The presented micrographs provide no quantification, instead, on close inspection, raise the question whether DAPT treatment might lead to pathological angiogenesis. The conclusions that (1) vascular density is increased and (2) that functional neoangiogenesis is induced are thus not valid.

It is stated that this model represents an ischemic model. However, there is surgical wounding of the skin as well as assumed impairment of blood flow during lifting. No evidence has been provided that indeed the lifting skin model induces significant ischemia, and VEGF expression can occur independent of ischemia. The effects in this model are most likely compounded and difficult to interpret.

We suggest that gene names and protein names should be named according to international nomenclature, for instance, Dll4 or Vegfa for RNA and DLL4 or VEGF for proteins.

In addition, primer sequences for primers stated in the methods, such as for Dll4 RNA, should be reported.

Furthermore, it is surprising that the scientific data are represented without error bars and numbers for individual experiments. Although significance values are given, the presentation of data does not conform to standard practice. In addition, there seems to be confusion about the actual data presented in Figures 6 and 7. Although the figure legends report mean values, the text refers to median values of VEGF and DLL4, respectively.

Clearly, conclusions about the clinical implications of the study in the context of ischemia should be made with caution, after all its "notch so easy."

Anne Limbourg, MD
Department of Plastic, Hand and Reconstructive Surgery, Hannover Medical School
Germany
limbourg.anne@mh-hannover.de

Peter Maria Vogt, MD
Department of Plastic, Hand and Reconstructive Surgery, Hannover Medical School
Germany

REFERENCES

1. Abbas O-L, Borman H, Terzi Y-K, et al. Inhibition of the notch pathway promotes flap survival by inducing functional neoangiogenesis. *Ann Plast Surg*. 2014; 75:455–462.
2. Limbourg A, Ploom M, Elligsen D, et al. Notch ligand delta-like 1 is essential for postnatal arteriogenesis. *Circ Res*. 2007;100:363–371.
3. Cristofaro B, Shi Y, Faria M, et al. Dll4-notch signaling determines the formation of native arterial collateral networks and arterial function in mouse ischemia models. *Development*. 2013;140:1720–1729.
4. Al Haj Zen A, Oikawa A, Bazan-Peregrino M, et al. Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia. *Circ Res*. 2010;107:283–293.
5. Carmeliet P, Jain R-K. Molecular mechanisms and clinical applications of angiogenesis. *Nature*. 2011; 473:298–307.
6. Phng L-K, Gerhardt H. Angiogenesis: a team effort coordinated by notch. *Dev Cell*. 2009;16:196–208.
7. Paris D, Quadros A, Patel N, et al. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. *Eur J Pharmacol*. 2005;514:1–15.
8. Benedito R, Rocha S-F, Woeste M, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. *Nature*. 2012; 484:110–114.
9. Simons M. Angiogenesis: where do we stand now? *Circulation*. 2005;111:1556–1566.

Inhibition of the Notch Pathway Promotes Flap Survival by Inducing Functional Angiogenesis: Reply

Dear Editor:

We would like to thank Dr. Limbourg for her comments and insight regarding our article entitled "Inhibition Of The Notch Pathway Promotes Flap Survival By Inducing Functional Angiogenesis."[1]

Previous studies have investigated the functional importance of the Notch during ischemia-induced angiogenesis using various models, such as ischemic hindlimb and myocardium.[2,3] In

Conflicts of interest and sources of funding: none declared.

ISSN: 0148-7043/15/7505-0579
DOI: 10.1097/SAP.0000000000000499

Conflicts of interest and sources of funding: none declared.

ISSN: 0148-7043/15/7505-0579
DOI: 10.1097/SAP.0000000000000500

this study, we preferred an applicable model to flap surgery in hopes of optimizing regenerative strategies for tissue reconstruction.

Because Notch signaling has multiple interactions with other pathways that include potential therapeutic targets, the cross-talks between Notch and VEGF pathways have garnered increasing attention. In contrast to the classical model represented in Figure 1, Benedito et al[4] found that Notch signaling has a little effect on VEGFR2 transcription. However, many recent studies have confirmed the strong correlation between Notch and VEGFR2 transcription rates.[5–7] We believe that further studies are required to characterize the detailed crosstalks between VEGF and Notch pathways.

Several studies have investigated whether inhibition of the Notch might affect angiogenesis. Notch inhibition increased vascular density through uncontrolled growth, resulting in disorganized and poorly perfused neovessel network.[8,9] We hypothesized that this nonfunctional nature of the neovessels can be a consequence of the high dosage of DLL4 inhibitor because several studies revealed that low dosage of Notch inhibition caused improved vascular function.[10,11] In the gamma secretase inhibitor (GSI)–treated group, histologic and microangiographic analyses revealed an increase in the number of the microvascular structures. Higher flap survival rates in this group suggest that the neomicrovascular network is functional, especially in the presence of angiograms revealing no significant difference in number and calibration of large arteries between the groups.

Notch inhibition has been achieved by several different mechanisms, including anti-Dll4 antibodies, DNA vaccination, soluble Dll4-Fc and Notch-Fc decoys, Notch antibodies, and GSIs. In our study, we preferred GSIs because they block signaling from all Notch receptors,[12] thus ruling out any possible angiogenic effects of other Notch ligands.

Apart from Notch inhibition, GSIs prevent the catalytic cleavage of several other membrane proteins such as erbB-4, CD44 and E-cadherin. In our study, we cannot rule out the possible effects of blocking such angiogenic proteins. However, several functions of the Notch during angiogenesis have been documented using only GSIs.[13,14] Even if GSIs have been used in addition to other Notch inhibition methods, this effect of GSIs cannot be ruled out.

In our study, GSIs were applied according to the manufacturer's recommendations. Because GSIs exert their function by disrupting the signaling of Notch receptors, we did not find it necessary to measure levels of DLL4 transcription to determine in vivo efficacy.

The Notch ligand DLL4 is most prominently expressed in tip cells, whereas Notch activation and subsequent signaling activity are regularly observed in the stalk cells through direct cell-cell interaction.[14] Interestingly, we found that blood levels for DLL4 in the surgery group were significantly higher than the control group. We think that the underlying mechanism is proteolytic shedding after upregulated transcription. However, we do not know whether these free soluble DLL4s have any functional importance. Because DLL4 ligands exert their function in the zone of ischemia, we do not believe that free circulating DLL4 ligands have any function in other normoperfused tissues. However, they may provide a negative feedback mechanism to control Notch pathway in the zone of ischemia. We are planning more detailed studies to determine the functional importance of these free circulating DLL4 proteins.

We used a modified McFarlane skin flap for the surgical portion of this study.[15] This flap was shown to be a reliable model in the study of skin ischemia with a predictable necrosis patterns.[16] In our study, both marginal necrosis and increased microvessel density are strong indicators of ischemia. We agree that surgical wounding can affect angiogenesis independent of ischemia. However, it is difficult to eliminate this factor in our in vivo flap model.

Primer sequences of the target genes for Real-Time Polymerase Chain Reaction Analysis were as follows:

VEGF	
Forward	5′ ACg AAA gCg CAA gAA ATC CC 3′
Reverse	5′ TTA ACT CAA gCT gCC TCg CC 3′
β-Actin	
Forward	5′ Agg gAA ATC gTg CgT gAC AT 3′
Reverse	5′ AAC CgC TCA TTg CCg ATA gT 3′
DLL4	
Forward	5′ TAC TgC Tgg TgT TgC Tgg TC 3′
Reverse	5′ gCA gCA ggg ATT Agg TTg TC 3′

Ozan Luay Abbas
From the Department of Plastic Surgery
Ahi Evran University Kırşehir
Merkez, Turkey
ozanluay@hotmail.com

REFERENCES

1. Abbas O-L, Borman H, Terzi Y-K, et al. Inhibition of the notch pathway promotes flap survival by inducing functional neoangiogenesis. *Ann Plast Surg*. 2014; 75:455–462.
2. Al Haj Zen A, Oikawa A, Bazan-Peregrino M, et al. Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia. *Circ Res*. 2010;107:283–293.
3. Yang Y, Duan W, Jin Z, et al. New role of Notch-mediated signaling pathway in myocardial ischemic preconditioning. *Med Hypotheses*. 2011;76: 427–428.
4. Benedito R, Rocha SF, Woeste M, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. *Nature*. 2012; 484:110–114.
5. Zou YH, Cao YQ, Wang LX, et al. gamma-secretase inhibitor up-regulates vascular endothelial growth factor receptor-2 and endothelial nitric oxide synthase. *Exp Ther Med*. 2011;2:725–729.
6. Zarkada G, Heinolainen K, Makinen T, et al. VEGFR3 does not sustain retinal angiogenesis without VEGFR2. *Proc Natl Acad Sci U S A*. 2015.
7. Wang H, Huang X, Zhang J, et al. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. *Clin Chim Acta*. 2014;436:243–248.
8. Kalen M, Heikura T, Karvinen H, et al. Gamma-secretase inhibitor treatment promotes VEGF-A-driven blood vessel growth and vascular leakage but disrupts neovascular perfusion. *PLoS One*. 2011;6: e18709.
9. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. *Nature*. 2006;444: 1083–1087.
10. Trindade A, Djokovic D, Gigante J, et al. Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. *PLoS One*. 2012;7:e29863.
11. Liu R, Trindade A, Sun Z, et al. Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues. *Biochem Biophys Res Commun*. 2012;418:173–179.
12. Rizzo P, Osipo C, Foreman K, et al. Rational targeting of Notch signaling in cancer. *Oncogene*. 2008;27:5124–5131.
13. Kalantari E, Saeidi H, Kia NS, et al. Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice. *Adv Biomed Res*. 2013;2:83.
14. Cao L, Arany PR, Wang YS, et al. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. *Biomaterials*. 2009; 30:4085–4093.
15. Lin DS, Zheng X, Li ZJ, et al. Effect of hirudin on random skin flap survival in rats. *Zhonghua Zheng Xing Wai Ke Za Zhi*. 2011;27:35–39.
16. McFarlane RM, Deyoung G, Henry RA. The design of a pedicle flap in the rat to study necrosis and its prevention. *Plast Reconstr Surg*. 1965;35:177–182.

Reconstruction of a Large External Hemipelvectomy Defect After Chordoma Resection Using a 5-Component Chimeric Rotational Flap

To the Editor:

We read with interest the article by Durden et al.[1] We want to congratulate them for the fascinating method which they present for the reconstruction of an external hemipelvectomy defect. We agree with the importance of reconstructing bone and soft tissue to restore form and function as much as possible,

Conflicts of interest and sources of funding: none declared.

ISSN: 0148-7043/15/7505-0580
DOI: 10.1097/SAP.0000000000000616